Corporate benefits teams are congratulating themselves for a decision that will look worse every year it ages. Dropping GLP-1 coverage to control 2026 costs is being framed as prudence. It is closer to eating your seed corn and calling it a diet.
The retreat is underway
In 2025, nearly half of large employers covered GLP-1 medications for weight loss. In 2026 that is reversing: 6 percent of employers with 500-plus workers dropped coverage, another 5 percent are considering it for 2027, and 51 percent named GLP-1s as the top driver of rising drug costs. Many that kept coverage tightened eligibility, raising the required BMI threshold from 30 to 35. The direction is unmistakable, and the logic is understandable. It is also short-sighted.
The math that gets ignored
The sticker shock is real: list prices run $1,000 to $1,350 a month, and even after discounts plan sponsors may net $569 to $664 per member. Against a single annual budget that is brutal. But the horizon matters enormously:
- Diabetes patients adhering to GLP-1s saw medical costs fall 6 to 9 percent after 30 months versus non-users.
- Weight-loss users showed 3 to 7 percent lower costs within 18 months.
- The avoided costs, heart disease, kidney failure, joint replacement, land years later, often after the employee has changed jobs.
- SHRM and other analyses point to lower total health spending over a multi-year horizon, precisely the horizon a single annual benefits budget is built to ignore.
The incentive trap
This is the honest crux, and it is uncomfortable. American job tenure is short enough that the employer paying today for a drug rarely captures tomorrow's savings; a competitor, or Medicare, does. So each firm rationally cuts coverage while the system as a whole swallows the downstream cost of untreated obesity. It is a textbook collective-action failure, and no amount of tut-tutting at benefits managers fixes an incentive structure that punishes long-term thinking.
What would actually work
The answer is not to shame employers into eating costs they cannot recoup. It is to change who bears the long horizon:
- Outcome-based pricing so manufacturers share risk when patients discontinue or regain weight.
- Portability mechanisms so the entity capturing eventual savings, often the public system, helps fund the up-front spend.
- Tighter but clinically honest eligibility, targeting the highest-risk patients where the cost-benefit is clearest, rather than blanket cuts.
There is a version of GLP-1 skepticism that is responsible: these drugs are new, adherence is imperfect, and blanket coverage of a $700-a-month medication for tens of millions is a legitimate fiscal question. But the 2026 retreat is not that careful conversation. It is quarterly budget management dressed as strategy, booking a guaranteed cost tomorrow to avoid a visible one today. Employers are free to make that trade. They should just stop calling it prudent.